Get the Stockscreener App
58.86
1.37%
-0.82
After Hours:
58.86
Protagonist Therapeutics Inc stock is traded at $58.86, with a volume of 649.52K.
It is down -1.37% in the last 24 hours and up +7.94% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$59.68
Open:
$60.4
24h Volume:
649.52K
Relative Volume:
0.80
Market Cap:
$3.66B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
22.47
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
-2.76%
1M Performance:
+7.94%
6M Performance:
+2.10%
1Y Performance:
+28.94%
1-Day Range:
$58.75
$60.40
1-Week Range:
$54.50
$60.40
52-Week Range:
$33.31
$61.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
58.86 | 3.59B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 8.7%Time to Sell? - MarketBeat
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
PTGX: Leerink Partners Initiates Coverage with Outperform Rating - GuruFocus
Great Lakes Advisors LLC Acquires 90,371 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target - MarketScreener
Adage Capital Partners GP L.L.C. Invests $16.61 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
State of Wyoming Has $70,000 Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
First Oral IL-23 Blocker Shows Superior Results: Protagonist's Icotrokinra Aims to Transform Psoriasis Care - Stock Titan
Woodline Partners LP Grows Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Axiom Investors LLC DE Takes $1.93 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Coppell Advisory Solutions LLC Makes New $947,000 Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
New Vernon Capital Holdings II LLC Purchases 345,034 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Scientech Research LLC Buys 6,217 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications - MSN
175,184 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Checkpoint Capital L.P. - MarketBeat
EFG Asset Management North America Corp. Invests $3.44 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Polycythemia Vera Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis - The Globe and Mail
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Gadsden Times
Protagonist Therapeutics, Inc. $PTGX is BVF Inc. IL's 6th Largest Position - MarketBeat
Will Protagonist Therapeutics Inc. Hold Gains Into CloseInsider Buying & Risk Controlled Stock Alerts - beatles.ru
Those Who Invested in Protagonist Therapeutics (NASDAQ:PTGX) Three Years Ago Are up 573% - 富途牛牛
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by 683 Capital Management LLC - MarketBeat
Will Protagonist Therapeutics Inc. benefit from geopolitical trends2025 Technical Patterns & Long Hold Capital Preservation Plans - beatles.ru
ADAR1 Capital Management LLC Trims Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
149,908 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Panagora Asset Management Inc. - MarketBeat
HighTower Advisors LLC Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Applying Wyckoff theory to Protagonist Therapeutics Inc. stock2025 Biggest Moves & Safe Swing Trade Setups - Newser
Is Protagonist Therapeutics Inc. a cyclical or defensive stock2025 Risk Factors & Real-Time Sentiment Analysis - خودرو بانک
What is Protagonist Therapeutics Inc. s revenue forecastJuly 2025 Short Interest & High Return Trade Guides - خودرو بانک
Magnetar Financial LLC Invests $539,000 in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Aug Levels: Is Protagonist Therapeutics Inc. in a bullish channelEarnings Recap Report & Weekly High Return Stock Opportunities - classian.co.kr
Institutional scanner results for Protagonist Therapeutics Inc.July 2025 Outlook & Community Supported Trade Ideas - Newser
Live market analysis of Protagonist Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - Newser
What’s the recovery path for long term holders of Protagonist Therapeutics Inc.July 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Can Protagonist Therapeutics Inc. expand into new markets2025 Fundamental Recap & Reliable Price Breakout Signals - خودرو بانک
Is Protagonist Therapeutics Inc. affected by consumer sentiment2025 Volume Leaders & AI Driven Stock Reports - خودرو بانک
Driehaus Capital Management LLC Has $11.37 Million Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Custom watchlist performance reports with Protagonist Therapeutics Inc.July 2025 Review & Reliable Momentum Entry Alerts - Newser
Can volume confirm reversal in Protagonist Therapeutics Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Will Protagonist Therapeutics Inc. benefit from rate cutsCPI Data & Technical Pattern Recognition Alerts - خودرو بانک
Is Protagonist Therapeutics Inc. vulnerable to short sellers2025 EndofYear Setup & Entry Point Confirmation Signals - خودرو بانک
Is Protagonist Therapeutics Inc. in a bullish channel2025 Support & Resistance & Consistent Profit Trading Strategies - خودرو بانک
How is Protagonist Therapeutics Inc. managing supply chain issues2025 Year in Review & Verified Momentum Stock Ideas - خودرو بانک
Using Ichimoku Cloud for Protagonist Therapeutics Inc. technicalsRate Cut & Daily Profit Maximizing Trade Tips - Newser
Applying big data sentiment scoring on Protagonist Therapeutics Inc.Market Risk Analysis & Weekly High Potential Stock Alerts - Newser
Can Protagonist Therapeutics Inc. continue delivering strong returns2025 Pullback Review & AI Powered Buy/Sell Recommendations - khodrobank.com
What momentum shifts mean for Protagonist Therapeutics Inc.Weekly Trade Summary & Daily Volume Surge Signals - Newser
Comparing Protagonist Therapeutics Inc. in custom built stock radarsTrade Risk Report & Detailed Earnings Play Alerts - Newser
Will Protagonist Therapeutics Inc. stock go up soon2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
Technical analysis overview for Protagonist Therapeutics Inc. stock2025 Price Momentum & Reliable Entry Point Trade Alerts - Newser
Northern Trust Corp Buys 10,927 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):